| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1997;29:560-563.)
© 1997 American Heart Association, Inc.
Articles |
Limited Echocardiography for Hypertensive Left Ventricular Hypertrophy
Mayo Clinic, Rochester, Minn, and Ochsner Clinic, New Orleans, La.
Correspondence to Sheldon G. Sheps, MD, Division of Hypertension, Mayo Clinic, West 9, 200 First St SW, Rochester, MN 55905. E-mail ssheps@mayo.edu
Key Words: echocardiography • hypertrophy, left ventricular • technology assessment, biomedical
 |
Introduction |
|---|
 Top Introduction TechnologyRecommendations for the Use...Cost ConsiderationsEconomic Information About...References |
|---|
Echocardiographic assessment of left ventricular (LV) mass has provided the best noninvasive information to permit diagnostic, therapeutic, and prognostic assessment of hypertensive heart disease1 2 3 4 5 6 7 (Table 1
). Reversal of hypertension-induced LV hypertrophy (LVH) occurs with all pharmacological (and some nonpharmacological) antihypertensive treatment, although few data are yet available to demonstrate that such reversal is associated with a reduced risk of LVH. However, one recent report suggested that patients who had changes of reversal of LVH (by electrocardiography [ECG]) were at substantially reduced risk compared with those who did not demonstrate diminished LVH.9 However, the cost of echocardiography has limited its utility in patients with hypertension. A less time-consuming and less-expensive LVH screening echocardiogram would be of great value; such a procedure is referred to as a limited echocardiogram.10
|
|
Technology |
|---|
|
TopIntroductionTechnologyRecommendations for the Use...Cost ConsiderationsEconomic Information About...References |
|---|
Echocardiography has been used as a standard procedure for the calculation of LV muscle mass for more than 25 years.11 Primary measurements of LV dimensions are made according to American Society of Echocardiography standards using the leading edge method of interface recognition and by identifying end diastole and end systole at the QRS onset and nadir of posterior systolic motion of the interventricular septum.12 13 14 Adequate M-mode images for calculation of LV mass can be obtained in approximately 90% of patients in an experienced echo laboratory.15 16 17 Assessment of the degree of LVH should include measurements of the posterior wall and septal thickness and calculation of LV mass index. However, even in patients with good-quality studies, there is significant intrareader and interreader variability of LV mass.15 For instance, in the Treatment of Mild Hypertension Study, the variance between the two readers was 23.8% (49.2g), and the intrareader variance was approximately 8.5%. Temporal variability of LV mass measurements in hypertensive patients and normotensive subjects was also highly variable.18 19 20
LVH can also be assessed by methods that are simpler or more complex than conventional echocardiography. Less complex and less expensive are ECG methods; but classic ECG criteria, although accurate when positive, are highly insensitive, identifying only 20% of patients with true LVH.21 22 23 At the other extreme of the technology spectrum, the most precise index of LV geometry can be obtained by the three-dimensional imaging technologies. Thus, ECG-gated magnetic resonance imaging, computed tomography, and three-dimensional echocardiography also provide LV mass and volume with great precision24 25 26 but at a higher cost and with varied availability. Patients with marked obesity and severe chronic obstructive lung disease may provide poor images, and subcostal imaging may yield a more useful study instead of the standard approach. Transesophageal echocardiography, which provides excellent cardiac images, can be used in selected circumstances for assessment of LVH, but this procedure is not recommended routinely.
|
Recommendations for the Use of Limited Echocardiography |
|---|
|
TopIntroductionTechnologyRecommendations for the Use...Cost ConsiderationsEconomic Information About...References |
|---|
The use of the limited echocardiogram for assessment of LVH risk is appropriate in untreated hypertensive patients with stage 1 blood pressure levels (systolic pressure 140 to 159 mm Hg and/or diastolic pressure 90 to 99 mm Hg) and no other evidence of LVH or other cardiovascular risk factors, and a standardized, high-quality procedure is feasible. It should not be obtained routinely in all patients with hypertension, nor should it be used for therapy selection because all classes of antihypertensive agents will diminish LV mass, providing that blood pressure is controlled. Identification of increased LV mass in an individual having hypertension of lesser stages of severity (eg, "high normal," stage 1 primarily and stage 2 rarely) is extremely valuable in helping the clinician decide whether to initiate antihypertensive drug therapy. However, in patients with stages 2 through 4 blood pressure levels (systolic pressure
160 mm Hg and/or diastolic pressure 100 mm Hg) or those with LVH and/or other cardiovascular risk factors associated with stage 1 or 2 hypertension, identification of echocardiographic evidence of increased LV mass is unnecessary because in these patients, vigorous control of pressure with antihypertensive therapy is already necessary. Follow-up limited echocardiograms in patients whose LV mass is already known is not indicated if blood pressure has not been controlled successfully. In such patients, further and more aggressive management with optimal control of pressure is clearly required. Office, ambulatory, and self blood pressure measurements (at work and home) would indicate whether blood pressure has been successfully reduced and controlled. Finally, one should not consider reduction of LV mass as a substitute for prevention of cardiovascular disease events when assessing the success of an antihypertensive agent.
Indications and situations when limited echocardiography is and is not indicated are presented in Tables 2 and 3, respectively.
|
|
|
Cost Considerations |
|---|
|
TopIntroductionTechnologyRecommendations for the Use...Cost ConsiderationsEconomic Information About...References |
|---|
When a more targeted approach to the management of hypertensive patients at higher risk is being considered, the availability of limited echocardiography would allow carefully selected hypertensive patients to undergo useful risk stratification, possibly without increasing the aggregate amount of financial and technical resources used. Although some younger patients with hypertension may be undergoing a more comprehensive echocardiographic procedure for other specific clinical indications, it may be more appropriate and cost-effective to obtain limited echocardiograms for these younger patients when the primary clinical issue is assessment of LVH.
One recent report indicated that in asymptomatic patients with hypertension and a normal clinical cardiac examination, a limited echocardiographic study rarely misses significant LVH.17 Moreover, any further clinically relevant information would be provided by a more comprehensive echocardiographic study in less than 10% of patients.17 When the expense of long-term antihypertensive drug therapy, especially for newer drugs, is being considered, it may be more cost conserving to use limited echocardiography as part of a screening strategy for initiating antihypertensive drug treatment.27 28
The more comprehensive and costly M-mode, 2-D, and Doppler echocardiographic evaluations may be warranted in the following patients: (1) hypertensive patients with chest pain, unexplained dyspnea, or other cardiac symptoms to assess LV systolic or diastolic function; (2) patients with systolic or diastolic murmurs to help define their cause or significance; and (3) patients with comorbid cardiac problems. More comprehensive echocardiographic examination may also be of value in distinguishing physiological from pathological hypertrophy in athletes.
|
Economic Information About Limited Echocardiography |
|---|
|
TopIntroductionTechnologyRecommendations for the Use...Cost ConsiderationsEconomic Information About...References |
|---|
The Medicare claims data analyzed initially by the American Medical Association for 1992 through 1994 were reviewed and the following noted: (1) The volume of 2-D, M-mode echocardiograms (CPT code 93307) increased over that period from 3 191 922 to 3 596 686; (2) the volume of limited echocardiograms (CPT code 93308) declined for the same period from 53 131 to 43 110 (Figure
); (3) in 1994, essential hypertension was one of the top eight diagnostic codes listed on claims that included 2-D, M-mode echocardiography (CPT code 93307), and 7% of the claims for that procedure had an associated diagnosis of essential hypertension (ICD-6 code 401); and (4) on a line-item basis for echocardiography performed in 1994, essential hypertension was listed as one of the top eight diagnostic codes, representing 4% of the diagnoses identified as justifying this procedure (these data are consistent with limited echocardiographic Medicare data from 1986 to 1993).
|
The foregoing data, although interesting, must be cautiously interpreted before any conclusions are drawn regarding the actual current use of limited and/or 2-D, M-mode echocardiography for the evaluation of hypertensive LVH. Since justification for this procedure may have been considered disallowable, an alternative diagnosis may have been selected. Other potentially useful data sets (eg, the Uniform Hospital Discharge Data Set, or UHDDS) have not been evaluated to delineate further the precise utilization of these procedures in the overall hypertensive population and to support or refute the Medicare claims data findings. The only known and available data are presented in this report.
Medicare has two data files that have been of particular value. The American College of Cardiology has analyzed the 1986-1993 Medicare procedure files, which include 100% of actual claims (submitted by physicians through the Part B Medicare Annual Data (BMAD) files) (Table 4). In addition, the Medicare beneficiary file has proved useful. The latter file consists of a 5% longitudinal sampling of all beneficiaries capturing code ICD-9 diagnostic aligned with each procedure code; this is required by the Health Care Financing Administration as a means of justifying the procedure. The CPT codes used to identify echocardiographic services have been in a state of flux for years and have undergone coding changes. Before 1990, two coding systems existed, one for radiology (70000 series) and the other for cardiology (93300 series). At the same time, evolution of the technology led to consolidation of the codes (2-D, M-mode, etc). These issues have obviously complicated the data.
|
Possible explanations for the reduction in the frequency of utilization of limited echocardiograms during the later period include: (1) A general awareness developed that a more limited procedure was not broadly appreciated by the physicians interested in the study; (2) greater third-party reimbursement was available by ordering 2-D, M-mode, and Doppler echocardiograms; and (3) with the broadened interest of physicians in hypertensive heart disease, those who were concerned about that problem may have ordered the more costly procedure without considering a less-expensive alternative. This possibility seems likely, especially when one considers that the concept of limited echocardiography had not been recommended broadly in peer-reviewed cardiovascular journal articles.
In conclusion, echocardiography is a safe, sensitive, and accurate tool for assessment of cardiac function in patients with hypertension. Despite some limitations, the determination of LV mass by echocardiography is a powerful predictor of cardiovascular risk. Limited echocardiography has been used less frequently in recent years. A limited echocardiogram for the detection of increased LV mass in carefully selected hypertensive patients would be appropriate in a targeted approach to the detection of patients at increased risk as part of a program to reduce their morbidity and mortality by the use of antihypertensive medications in addition to lifestyle changes. The overall effect could be a reduction in the cost of the lifetime management of hypertension in those selected patients.
|
Acknowledgments |
|---|
The authors gratefully acknowledge guidance from Drs Henry R. Black, Richard E. Devereux, Tonette Krousel-Wood, Daniel Levy, Philip R. Liebson, Barry M. Massie, Franz H. Messerli, Jack P. Segal, Clarence Shub, and James V. Talano. Each individual is an eminent authority in one or more of the following fields: cardiovascular medicine, hypertensive diseases, echocardiography, cardiovascular epidemiology, or healthcare analysis.
Received June 11, 1996;
first decision July 8, 1996;
first decision September 11, 1996;
|
References |
|---|
|
TopIntroductionTechnologyRecommendations for the Use...Cost ConsiderationsEconomic Information About...References |
|---|
1. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C. The heart in hypertension. N Engl J Med. 1992;327:998-1008.[Medline] [Order article via Infotrieve]
2. Levy D, Garrison RI, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.[Abstract]
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med. 1989;110:101-107.
4.
Bikina M, Evans JC, Larson MG, Benjamin EJ, Levy D. Left ventricular mass and risk of stroke in a elderly cohort: The Framingham Heart Study. JAMA. 1994;272:33-36.
5. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-178.
6. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
7. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:831-836.
8. Lauer MS. Left ventricular hypertrophy and cardiovascular prognosis. Cleve Clin J Med. 1995;62:169-175.[Medline] [Order article via Infotrieve]
9.
Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subject with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
10. Black HR, Weltin G, Jaffe CC. The limited echocardiogram: a modification of standard echocardiography for use in the routine evaluation of patients with systemic hypertension. Am J Cardiol. 1991;67:1027-1030.[Medline] [Order article via Infotrieve]
11. Devereux RB, Liebson PR, Horan MJ. Recommendations concerning the use of echocardiography in hypertension and general population research. Hypertension. 1987;9(suppl II):II-97-II-104.
12. Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure by echocardiography and other noninvasive techniques. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, Management. 2nd ed. New York, NY: Raven Press Publishers; 1995:1969-1985.
13.
Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-mode Standardization of the American Society of Echocardiography: recommendations regarding measurements. Circulation. 1978;58:1072-1083.
14. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Shah D, Schnittger I, Silverman NH, Tajik AJ. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiogram: recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358-367.[Medline] [Order article via Infotrieve]
15.
Liebson PR, Grandits G, Prance R, Dianzumba S, Flack JM, Cutler JA, Grimm R, Stamler J. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1993;87:476-486.
16. Shub C, Klein AL, Zachariah PK, Baily KR, Tajik AJ. Determination of left ventricular mass by echocardiography in a normal population: effect of age and sex in addition to body size. Mayo Clin Proc. 1994;69:205-211.[Medline] [Order article via Infotrieve]
17. Shub C, Tajik AJ, Sheps SG. Value of two-dimensional echocardiography and Doppler examination in the assessment of hypertensive patients: a pilot study. J Am Soc Echocardiogr. 1995;8:280-284.[Medline] [Order article via Infotrieve]
18. Gottdiener JS, Livengood SV, Meyers PS, Chase GA. Should echocardiography be performed to assess effets of antihypertensive therapy? Test-retest reliability of edhocardiography for measurement of left ventricular for measurement of left ventricular mass and function. J Amer Col Cardiol. 1995;25:424-430.
19. Wallerson DC, Devereux RB. Reproducibility of echocardiographic left ventricular measurements. Hypertension. 1987;9(suppl II):II-6-II-18.
20. de Simone G, Ganau A, Verdecchia P, Devereux RB. Echocardiography in arterial hypertension: when, why and how. J Hypertens. 1994;12:1129-1136.[Medline] [Order article via Infotrieve]
21.
Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer electrocardiogram interpretation: validation with autopsy findings. Circulation. 1987;75:565-572.
22. Norman JE, Levy D, Campbell G, Bailey JJ. Improved detection of echocardiographic left ventricular hypertrophy using a new electrocardiographic algorithm. J Am Coll Cardiol. 1993;21:1680-1688.[Abstract]
23. Molloy T, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;20:1180-1186.[Abstract]
24.
Feiring AJ, Rumberger JA, Reiter SJ, Skorton DJ, Collens SM, Lipton MJ, Higgins CB, Ell S, Marcus ML. Determination of left ventricular mass in dogs with rapid-acquisition cardiac computed tomographic scanning. Circulation. 1985;72:1355-1364.
25. Keller AM, Peshock RM, Malloy CR, Buja LM, Nunnally R, Parkey RW, Willerson JT. In vivo measurement of myocardial mass using nuclear magnetic resonance imaging. J Am Coll Cardiol. 1986;8:113-117.[Abstract]
26. Gopal AS, Keller AM, Shen Z, Sapin PM, Schroeder KM, King DL Jr, King DL. Three dimensional echo: in vitro and in vivo validation of LV mass and comparison with conventional echocardiographic methods. J Am Coll Cardiol. 1994;24:504-513.[Abstract]
27.
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1992 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med. 1993;153:154-183.
28.
Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
This article has been cited by other articles:
 |
|
 |
|
  C. M. Ferrario, J. Basile, W. Bestermann, E. Frohlich, M. Houston, D. T. Lackland, R. D. Smith, and D. L. Wise Review: The role of noninvasive hemodynamic monitoring in the evaluation and treatment of hypertension Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 113 - 118. [Abstract] [PDF]
|
|
|
|
 |
|
 A. D. Waggoner Echocardiographic Assessment of Left Ventricular Structure in Hypertension and the Impact on Clinical Outcomes Journal of Diagnostic Medical Sonography, September 1, 2004; 20(5): 304 - 314. [Abstract] [PDF]
|
|
|
|
 |
|
 J R T C Roelandt Ultrasound stethoscopy: a renaissance of the physical examination? Heart, September 1, 2003; 89(9): 971 - 973. [Full Text] [PDF]
|
|
|
|
|
|
E C Vourvouri, L Y Koroleva, F J Ten Cate, D Poldermans, A F L Schinkel, R T van Domburg, W B Vletter, and J R T C Roelandt Clinical utility and cost effectiveness of a personal ultrasound imager for cardiac evaluation during consultation rounds in patients with suspected cardiac disease Heart, July 1, 2003; 89(7): 727 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.C. Vourvouri, D. Poldermans, A.F.L. Schinkel, L.Y. Koroleva, F.B. Sozzi, G.E. Parharidis, J.J. Bax, and J.R.T.C. Roelandt Left ventricular hypertrophy screening using a hand-held ultrasound device Eur. Heart J., October 1, 2002; 23(19): 1516 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Vasan, E. J. Benjamin, M. G. Larson, E. P. Leip, T. J. Wang, P. W. F. Wilson, and D. Levy Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic Dysfunction: The Framingham Heart Study JAMA, September 11, 2002; 288(10): 1252 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.R.T.C Roelandt A personal ultrasound imager (ultrasound stethoscope). A revolution in the physical cardiac diagnosis! Eur. Heart J., April 1, 2002; 23(7): 523 - 527. [Full Text] [PDF]
|
|
|
|
 |
|
 The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med, November 24, 1997; 157(21): 2413 - 2446. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||